Canadian life sciences company Nirvana Life Sciences Inc. (CSE: NIRV), focused on research & development of non-addictive pain management and relapse prevention products for pain and addictions, has been granted approval to build its R&D facility in Vancouver by Canada’s governmental department of Health.
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its therapeutic retreats in Jamaica and Optimi Health Corp.
After a prosperous Miami event this past April, the Benzinga Cannabis Capital Conference will take place in Chicago on September 13-14. As always, the meeting will host leading executives and investors who will talk about the industry’s present and future.
Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).
Pharmala Biotech Holdings Inc. (CSE: MDMA), a company focused on research, development and manufacturing of MDMA and similar class molecules, has registered a trademark for its clinical-grade, Good Manufacturing Practice MDMA product, to be available as “Laneo MDMA.”
Biotech company Small Pharma Inc. (OTCQB: DMTTF), producer of short-acting psychedelic-assisted therapies for diverse mental health conditions, announced its financial results earlier this month for the fiscal year ended Feb. 28, 2022.
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.